FDAnews
www.fdanews.com/articles/197803-imperial-college-london-doses-first-participant-in-covid-19-vaccine-study
UKflag.jpg

Imperial College London Doses First Participant in COVID-19 Vaccine Study

June 26, 2020

Imperial College London has dosed its first participant in a phase 1 trial of its RNA-based COVID-19 vaccine candidate.

The trial will assess the vaccine’s safety and find the optimal dosage. For the initial stage, 15 healthy volunteers will receive the vaccine, starting with a low dose and escalating to higher doses for subsequent volunteers.

The college plans to enroll 300 healthy participants over the coming weeks and to begin larger trials later this year.

View today's stories